Effect of peroxisome proliferator-activated receptor gamma agonist (pioglitazone) and methotrexate on disease activity in rheumatoid arthritis (experimental and clinical study)

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Volumn 4, Issue , 2011, Pages 1-10

  Shahin, Dina ^a   el Toraby, Ehab ^a   Abdel Malek, Hala ^a   Boshra, Vivian ^a   Elsamanoudy, Ayman Z ^a   Shaheen, Dalia ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Anti inflammatory; Disease activity; Oxidative stress; Pioglitazone; PPAR agonist; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GLUTATHIONE; INTERLEUKIN 1BETA; METHOTREXATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY FOR 28 JOINT INDEX; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; EXPERIMENTAL STUDY; HUMAN; LIPID PEROXIDATION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROSPECTIVE STUDY; RAT; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; WEIGHT GAIN;

EID: 79958160488     PISSN: 11795441     EISSN: 11795441     Source Type: Journal    
DOI: 10.4137/CMAMD.S5951     Document Type: Article

References (47)

1. Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatology. 2007;26:1228-33.
2. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35:8-17.
3. Karvounaris SA, Sidiropoulos PI, Papadakis JA, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, crosssectional, controlled, study. Ann Rheum Dis. 2007;66(1): 28-33.
4. Shahin D, Eltoraby E, Mesbah A, Houssen M. Insulin resistance in early untreated rheumatoid arthritis patients. Clinical Biochemistry. 2010;43: 661-5.
5. Larsen TM, Toubro S, Astrup A. PPAR gamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long term efficacy? International Journal of Obesity. 2003;27:147-61.
6. Rosen ED, Speigelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Che. 2001;276:37731-34.
7. Jiang C, Ting AT, Seed B. PPAR γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-6.
8. Fahmi H, Di Battista JA, Pelletier JP, et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1 beta-induced nitric oxide, matrix metalloproteinase 13 production in human chondrocytes: Arthritis Rheum. 2001;44:595-607.
9. Mix KS, Coon CI, Rosen ED, Suh N, Sporn MB, Brinckerhoff CE. Perixisome proliferator- activated receptor-γ- independent repression of collagenase gene expression by 2-cyano-3,12- dioxooleana-1,9-dien-28-oic acid and prostaglandin15-deoxy-Δ(12,14) J2: a role for smad signaling. Mol Pharmacol. 2004;65:309-18.
10. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor {gamma} ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol. 2005;288:C899-905.
11. Verrier E, Wang L, Wadham C, et al. PPARγ agonists ameliorate endothelial cell activation via inhibition of diacylglycerol- protein kinase C signaling pathway. Role of diacylglycerol Kinase. Circ Res. 2004;94:1515-22.
12. Clarke RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula S. The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. J Immunol. 2000;164: 1346-71.
13. Harris SG, Phipps RP. The nuclear receptor PPARγ is expressed by mouse T lymphocytes and PPAR γ agonists induce apoptosis. Eur J Immunol. 2001;31:1098-105.
14. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273(40):25573-80.
15. Billingham MEJ. Models of arthritis, the search for anti-arthritic drugs. Pharmacol Ther. 1983;21:389-428.
16. Bendele AM, McComb J, Gould T, et al. Animal models of arthritis: relevance to human disease. Toxicologic Pathol. 1999;27:134-42.
17. Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPAR agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats Cardiovascular Research. 2005;66(1):150-61.
18. Bakharevski O, Stein-Oakley AN, Thomson NM, Ryan PF. Collagen induced arthritis in rats: Contrasting effect of subcutaneous versus intradermal inoculation of type II collagen. Rheumatol. 1998;25: 1945-52.
19. Wang CX, Olschowka JA, Wrathall JR. Increase of interleukin-1β RNA, protein in the spinal cord following experimental traumatic injury in the rat. Brain research. 1997;759(2):190-6.
20. Guo L, Ye C, Chen W, et al. Anti-inflammatory, analgesic potency of carboxyamidotriazole, a tumorostatic agent. J Pharmacol Exp Ther. 2008; 325(1):10-6.
21. Botsoglou NA. Rapid, Sensitive, specific thiobarbituric acid method for measuring lipid peroxidation in animal tissue, food, feedstuff samples. J Agric Food Chem. 1994;42(9):1931-7.
22. Baillie TA, Slatter JG. Glutathione: a vehicle for the transport of chemically reactive metabolites in vivo. Acc. Chem Res. 1991;24(9):264-70.
23. Beckman JS, Koppenol WH. Nitric oxide, superoxide, peroxynitrite: the good, the bad, ugly. Am J Physio Cell Physiol. 1996;271:C1424-37.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
25. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46:614-24.
26. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev. 2003;2:346-57.
27. Ostrakhovitch E, Afanasev I. Oxidative stress in rheumatoid arthritis. Leukocytes suppression by rutin, other antioxidants, chelators. Biochem Pharmacol. 2001;62(6)(15):743-6.
28. Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, et al. Assessment of paraoxonase 1 activity, malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem. 2005;38:951-5.
29. Hassan M, Hadi R, Al-Rawi Z, Padron V, Stohs S. The glutathione defense system in the pathogenesis of rheumatoid arthritis. J Appl Toxicol. 2001; 21(1):69-73.
30. Jaswal S, Mehta HC, Sood AK, Kaur J. Antioxidant status in rheumatoid arthritis role of antioxidant therapy. Clin Chim Acta. 2003;338(1-2):123-9.
31. Kamanli A, Naziroglu M, Aydilek N, Hacievliyagil C. Plasma lipid peroxidation, antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct. 2004;22(1):53-7.
32. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers, patients with rheumatoid arthritis. Rheumatology. 2003;42: 1189-96.
33. Huang CC, Hsu PC, Hung YC, et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis. 2005;10:895-907.
34. Tomita T, Kakiuchi Y, Tsao PS. THR0921, a novelperoxisome proliferatoractivated receptor γ agonist, reduces the severity of collagen-induced arthritis. Arthritis Res Ther. 2006;8:R7.
35. Koufany M, Moulin D, Bianchi A, et al. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis Res Ther. 2008;10(1):R6.
36. Inoue H, Tanabe T, Umesono K. Feedback control of cyclooxygenase-2 expression through PPAR. J Biol Chem. 2000;275:28028-32.
37. Fahmi H, Pelletier JP, Martel-Pelletier J. PPAR gamma ligands as modulators of inflammatory, catabolic responses in arthritis. An overview. J Rheumatol. 2002;29(1):3-14.
38. Shiojiri T, Wada K, Nakajima A, et al. PPAR γ ligands inhibit nitrotyrosine formation, inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol. 2002;448:231-8.
39. Yamashita A, Yonemitsu Y, Okano S, et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol. 2002;168:450-7.
40. Racke MK, Gocke AR, Mark Muir, et al. Nuclear receptors and autoimmune disease. The potential of PPAR agonists to treat multiple sclerosis. J Nutr. 2006;136:700-3.
41. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator- activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
42. Sabatini M, Bardiot A, Lesur C, et al. Effects of agonists of peroxisome proliferator-activated receptor gamma on proteoglycan degradation and matrix metalloproteinase production in rat cartilage in vitro. Osteoarthritis Cartilage. 2002;10:673-9.
43. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor gamma activators. Circulation. 2002;101:235-8.
44. Sumariwalla PF, Palmer CD, Pickford LB, Feldmann M, Foxwell BMJ, Brennan FM. Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717. Rheumatology. 2009;48:32-8.
45. Bongartz T, Coras B, Vogt T, Schölmerich J, Müller-Ladner U. Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study. Rheumatology. 2005;44(1):126-9.
46. Patel HJ, Belvisi MG, Bishop-Bailey D, Yacoub MH, Mitchell JA. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy. J Immunol. 2003;170:2663-9.
47. Zou R, Xu G, Liu X, et al. PPARγ agonists inhibit TGF-β-PKA signaling in glomerulosclerosis. Acta Pharmacologica Sinica. 2010;31:43-50.